Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 May;24(5):867-70.

Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus

Affiliations
  • PMID: 9150074

Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus

M Mestanza-Peralta et al. J Rheumatol. 1997 May.

Abstract

Objective: To study the outcome of patients with idiopathic thrombocytopenic purpura (ITP) treated with splenectomy, with respect to the development of systemic lupus erythematosus (SLE).

Methods: Two independent observers reviewed data of 20 clinical, laboratory, and therapeutic variables of patients with ITP, with no clinical or laboratory indications of SLE, who were treated by splenectomy from 1952 to August 1995. 115 patients were studied, 86 female, 25 male, mean age 31.5 (SD 15.4) yrs (range 10-75), who had a mean followup of 7.2 (SD 7.5) yrs (range 0.08-32.8).

Results: 14 patients (12.1%) developed SLE. The most common SLE manifestations were arthritis (78.5%), lymphopenia (74.1%), mucocutaneous manifestations (64.2%), and hemolytic anemia (35.7%). Mortality was greater in the SLE group than in the ITP group (3 vs 4; odds ratio 6.61, 95% confidence interval 1.57-27.76, p = 0.037). 67% of the patients with ITP and 57.2% with SLE were in complete remission at the last visit (p = 0.54).

Conclusion: Almost one of 8 patients with splenectomy due to ITP developed SLE. These patients require periodic followup to monitor other clinical data of SLE.

PubMed Disclaimer

LinkOut - more resources